Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)

Developed for: respiratory syncytial virus infectious disease
Investigated by: Henan Center for Disease Control and Prevention · MAXVAX Biotechnology Limited Liability Company · Guangdong Center for Disease Prevention and Control · Hebei CDC ,China · Hubei Provincial Center for Disease Control and Prevention · Hunan Provincial Center for Disease Control and Prevention
+3 more
· Shaanxi Provincial Center for Disease Control and Prevention · Shandong Province Centers for Disease Control and Prevention · Sichuan Center for Disease Control and Prevention

202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 31 trial
Phase 3	NCT07272434	Oct 2025 → Jul 2026 overdue	respiratory syncytial virus infectious disease	MAXVAX Biotechnology Limited Liability Company	Recruiting	No outcome recorded
Phase not applicable1 trial
—	NCT07618325	Jun 2026 → Jun 2028 expected	respiratory syncytial virus infectious disease	MAXVAX Biotechnology Limited Liability Company	Not yet recruiting	No outcome recorded

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)	ClinicalTrials.gov intervention name — accepted as the source's own label NCT07272434 ↗ 1 NCT07618325 ↗
Known as	Recombinant RSV vaccine(CHO cell)	“This study will evaluate the efficacy of the Recombinant RSV vaccine(CHO cell) vaccine in preventing lower respiratory tract diseases(LRTD) caused by RSV in adults≥ 60 years of...” NCT07272434 ↗
Known as	RSV vaccine(CHO cell)	“This study will evaluate the efficacy of the Recombinant RSV vaccine(CHO cell) vaccine in preventing lower respiratory tract diseases(LRTD) caused by RSV in adults≥ 60 years of...” NCT07272434 ↗
Modality	Vaccine	“Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)” NCT07272434 ↗
Route	Intramuscular	“by IM injection into the deltoid region of the arm.” NCT07272434 ↗